Day: November 21, 2023

ST PETERSBURG, FL, Nov. 21, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – The Marquie Group, Inc.(OTCMKTS:TMGI), commonly referred to as “The Marquie Group”, “TMGI”, or the “Company”, is donating Whim personal care products to American military troops using the non-profit organization “For the Troops”. The Southern California Non-Profit is an all-volunteer run 501(c)(3) organization dedicated to providing members of the American military with ‘We Care’ packages containing basic necessities, goodies, games and—most of all—a show of support. Since its inception in 2005, For The Troops has distributed more than 250,000 packages to American troops who risk their lives overseas every day, far away from the comforts of home. Jacquie Angell, CEO of Simply Whim remarked, “I was thrilled to find the need for personal care products on the Troops’...

Hong Kong, Nov. 21, 2023 (GLOBE NEWSWIRE) — Alpha Technology Group Limited (NASDAQ: ATGL) (the “Company” or “Alpha”), an established cloud-based IT solution service provider in Hong Kong, today announced that Prime Number Capital LLC, as underwriter of the Company’s initial public offering (the “Offering”), has fully exercised the over-allotment option (the “Option”) to purchase an additional 262,500 Ordinary Shares at the public offering price of $4.00 per share. As a result, the Company has raised gross proceeds of $1,050,000, in addition to the previously gross proceeds of approximately $7,000,000, before deducting underwriting discounts and offering expenses, already received in the Offering. Prime Number Capital LLC acted as the sole bookrunner for the Offering. Hunter Taubman Fischer & Li LLC acted as U.S. counsel to...

NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) OR IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT. THE DISTRIBUTION OF THIS DOCUMENT IN CERTAIN JURISDICTIONS (IN PARTICULAR, THE UNITED STATES AND THE UNITED KINGDOM) MAY BE RESTRICTED BY LAW. Press release 21 November 2023 SSCP Lager BidCo AB (publ) successfully issues new senior secured floating rate notes of SEK 850 million, announces the results of the tender offer and gives conditional notice...

NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance 72 patients previously dosed with NXC-201 ex-U.S. First CAR-T program for light-chain (AL) Amyloidosis Favorable tolerability enables expansion into autoimmune indicationsLOS ANGELES, Nov. 21, 2023 (GLOBE NEWSWIRE) —  Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company advancing personalized therapies for oncology and immunology, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for BCMA CAR-T NXC-201 (formerly HBI0101). With this clearance, NEXICART-2 (NCT06097832) is to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to the United States. Favorable tolerability...

NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance 72 patients previously dosed with NXC-201 ex-U.S. First CAR-T program for light-chain (AL) Amyloidosis Favorable tolerability enables expansion into autoimmune indicationsLOS ANGELES, Nov. 21, 2023 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company advancing personalized therapies for oncology and immunology, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for BCMA CAR-T NXC-201 (formerly HBI0101). With this clearance, NEXICART-2 (NCT06097832) is to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to the United States. Favorable tolerability...